Novo Nordisk Annual Report 2017

Novo Nordisk Form 20-F

Corporate Governance Report

Featured articles

The healthcare agenda is changing, and business competition is increasing. To meet these challenges, Novo Nordisk’s future drug development ambitions call for a higher innovation threshold, expansion into other therapy areas and more external partnerships.

Read more

The conversation between a person with diabetes and their doctor usually focuses on blood glucose control. But living with diabetes comes with a number of life-threatening risks, including cardiovascular events and severe hypoglycaemic episodes – risks that novel diabetes treatments can now reduce. And so the conversation is changing.

Read more

The underlying cause of obesity is an energy imbalance between calories consumed and calories expended. But this is only part of the story. The science behind obesity is complex – and maintaining weight loss is not easy.

Read more

Annual Reports archive